Alfact Innovation Report issue

For profit Phase 2
Founded: Paris France (2006)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2010
NCT01318525
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

hepatocarcinoma-intestine-pancreas protein, human (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatic Insufficiency (Phase 2)

Liver Failure (Phase 2)

Liver Failure, Acute (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2